"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
Patients receiving OPTISON should be instructed to inform their healthcare provider if they:
- have a congenital heart defect, or recent worsening of heart or lung conditions;
- have had reactions to blood, blood products, albumin or a prior OPTISON administration (see CONTRAINDICATIONS and WARNINGS);
- may be pregnant or are nursing an infant.
Last reviewed on RxList: 9/6/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Optison Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.